BioSpace News Archive

Median Technologies and PASREL-Imagerie, announce the signing of an agreement to deliver cutting-edge imaging biomarkers for the development of new oncology drugs in the era of precision medicine.

Three recent patient research reports show that cellular remote patient monitoring™(RPM) programs are an effective way for patients to become more involved with their care between visits to their healthcare provider.

SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.

On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University’s esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians, Said Ibrahim, MD, MBA, MPH.

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date.

Syndax Pharmaceuticals, Inc. announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering.

Aadi Bioscience, Inc. (NASDAQ: AADI) today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.

Ensysce Biosciences, Inc., a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced that its most recent study has demonstrated crucially important data for PF614 on pain intensity efficacy and speed of onset.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that the first patient has initiated treatment at the Beverly Hills Cancer Center (BHCC) in the Company’s Deltacel-01 clinical trial.